1. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation.
- Author
-
Song CJ, Liu XS, Zhu Y, Chen LH, Jia W, Li YN, Cao YX, Xie X, Zhuang R, Zhu CS, and Jin BQ
- Subjects
- Apoptosis, Apoptosis Regulatory Proteins, Enzyme-Linked Immunosorbent Assay, HLA-DR4 Antigen blood, HLA-DR4 Antigen genetics, HLA-DR5 Antigen blood, HLA-DR5 Antigen genetics, Humans, Kidney Transplantation pathology, Membrane Glycoproteins blood, Membrane Glycoproteins genetics, Reference Values, TNF-Related Apoptosis-Inducing Ligand, Tumor Necrosis Factor-alpha genetics, HLA-DR4 Antigen analysis, HLA-DR5 Antigen analysis, Kidney Transplantation immunology, Membrane Glycoproteins analysis, Tumor Necrosis Factor-alpha analysis
- Abstract
Renal transplantation is the best treatment of some end-stage renal diseases. Unfortunately, not every transplant is successful due to the rejection or dysfunction of the transplanted kidney. Many cytokines participate in rejection by inducing inflammation or apoptosis. In this study, the expressions of TRAIL, DR4, and DR5 in rejected renal tissue and of serum soluble TRAIL (sTRAIL) in patients with kidney rejection were investigated by immunohistochemical staining and sandwich enzyme-linked immunosorbent assay, respectively. The results showed that the expression of TRAIL, DR4 and DR5, and serum sTRAIL levels were markedly upregulated among renal transplant patients. Since both membrane and soluble forms of TRAIL can induce apoptosis of DR4/DR5-expressing cells via recruiting FADD and caspase 8, elevated TRAIL and its receptors may participate in renal graft rejection., (Copyright 2004 Elsevier Inc.)
- Published
- 2004
- Full Text
- View/download PDF